Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Uveal Melanoma 1Prostatic Neoplasms 1Melanoma 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Injections, Intramuscular × Clear all
NCT03262103 2022-09-10

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Genitourinary

Prostatic Neoplasms

NCT00398073 2017-03-16

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
35 enrolled 9 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡